Faropenem resistance causes in vitro cross-resistance to carbapenems in ESBL-producing Escherichia coli

• Published in: International journal of antimicrobial agents Vol. 55; no. 3; p. 105902
• Main Authors: Gandra, Sumanth, Choi, JooHee, McElvania, Erin, Green, Stefan J., Harazin, Maureen, Thomson, Richard B., Dantas, Gautam, Singh, Kamal S., Das, Sanchita
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier B.V 01.03.2020
• Subjects: Anti-Bacterial Agents - pharmacology; beta-Lactamases - biosynthesis; beta-Lactams - pharmacology; carbapenem; Carbapenems - pharmacology; cross resistance; Drug Resistance, Bacterial - drug effects; Ertapenem - pharmacology; Escherichia coli - drug effects; Escherichia coli - metabolism; Escherichia coli Infections - drug therapy; Escherichia coli Infections - microbiology; faropenem; Humans; porin; Porins - biosynthesis; faropenem; carbapenem; cross resistance; porin

•Faropenem resistance among Escherichia coli isolates causes cross-resistance to carbapenems•Cross-resistance was seen in extended spectrum beta-lactamase (ESBL)-producing E. coli isolates tested•ESBL E. coli isolates with reduced susceptibility to carbapenems show ompC mutations Faropenem is an ora...